{"pmid": "8940983", "sentences": {"sent_1": {"Section": "METHODS", "text": "The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants .", "entities": {"entity_1": {"text": "immunogenicity", "class": "Outcome", "negation": 0, "UMLS": "", "start": 1}, "entity_2": {"text": "Haemophilus influenzae type B conjugate vaccines", "class": "Intervention", "negation": 0, "UMLS": "", "start": 4}, "entity_3": {"text": "primary vaccination series", "class": "Participant", "negation": 0, "UMLS": "", "start": 12}, "entity_4": {"text": "Philippine infants", "class": "Participant", "negation": 0, "UMLS": "", "start": 16}}, "relations": {}}, "sent_2": {"Section": "METHODS", "text": "Serum antibody responses to three Haemophilus influenzae type b ( Hib ) capsular polysaccharide-protein conjugate vaccine ( PRP-OMP , PRP-T , and HbOC ) were evaluated in 174 Philippine infants", "entities": {"entity_5": {"text": "antibody responses", "class": "Outcome", "negation": 0, "UMLS": "", "start": 1}, "entity_6": {"text": "Haemophilus influenzae type b ( Hib ) capsular polysaccharide-protein conjugate vaccine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 5}, "entity_7": {"text": "PRP-OMP", "class": "Intervention", "negation": 0, "UMLS": "", "start": 17}, "entity_8": {"text": "PRP-T", "class": "Intervention", "negation": 0, "UMLS": "", "start": 19}, "entity_9": {"text": "HbOC", "class": "Intervention", "negation": 0, "UMLS": "", "start": 22}, "entity_10": {"text": "Philippine infants", "class": "Participant", "negation": 0, "UMLS": "", "start": 28}}, "relations": {}}, "sent_3": {"Section": "METHODS", "text": "after a primary vaccination series .", "entities": {"entity_11": {"text": "primary vaccination series", "class": "Participant", "negation": 0, "UMLS": "", "start": 2}}, "relations": {}}, "sent_4": {"Section": "METHODS", "text": "Children were randomized to receive one of the Hib vaccines ( Hib groups ) or into a control group .", "entities": {"entity_12": {"text": "Children", "class": "Participant", "negation": 0, "UMLS": "", "start": 0}, "entity_13": {"text": "Hib vaccines", "class": "Intervention", "negation": 0, "UMLS": "", "start": 8}, "entity_14": {"text": "Hib", "class": "Intervention", "negation": 0, "UMLS": "", "start": 11}, "entity_15": {"text": "control", "class": "Intervention", "negation": 0, "UMLS": "", "start": 17}}, "relations": {}}, "sent_5": {"Section": "METHODS", "text": "Vaccination was carried out at six , 10 and 14 weeks of age based on the local Expanded Program of Immunization schedule .", "entities": {}, "relations": {}}, "sent_6": {"Section": "METHODS", "text": "Sera were collected at six weeks of age for the Hib groups and one month after the third dose for all subjects .", "entities": {"entity_16": {"text": "Sera", "class": "Outcome", "negation": 0, "UMLS": "", "start": 0}, "entity_17": {"text": "Hib", "class": "Intervention", "negation": 0, "UMLS": "", "start": 10}}, "relations": {}}, "sent_7": {"Section": "METHODS", "text": "Anti-Hib concentrations were determined by the Farr-type radioimmunoassay .", "entities": {"entity_18": {"text": "Anti-Hib concentrations", "class": "Outcome", "negation": 0, "UMLS": "", "start": 0}}, "relations": {}}, "sent_8": {"Section": "METHODS", "text": "There were no significant differences ( P = 0.3626 ) in the prevaccination anti-Hib geometric mean concentration ( GMC ) among the three Hib groups .", "entities": {"attribute_1": {"text": "significant differences", "class": "modifier", "negation": 0, "UMLS": "", "start": 3}, "attribute_2": {"text": "P = 0.3626", "class": "measure", "negation": 0, "UMLS": "", "start": 6}, "entity_19": {"text": "prevaccination anti-Hib geometric mean concentration ( GMC )", "class": "Outcome", "negation": 0, "UMLS": "", "start": 12}, "entity_20": {"text": "three Hib groups", "class": "Intervention", "negation": 0, "UMLS": "", "start": 22}}, "relations": {}}, "sent_9": {"Section": "METHODS", "text": "Differences in the GMC after the primary series of three doses were significant ( P < 0.0001 ) ; GMC was highest for PRP-T ( 6.62 micrograms/ml ) , followed", "entities": {"attribute_3": {"text": "Differences", "class": "modifier", "negation": 0, "UMLS": "", "start": 0}, "entity_21": {"text": "GMC", "class": "Outcome", "negation": 0, "UMLS": "", "start": 3}, "attribute_4": {"text": "P < 0.0001", "class": "measure", "negation": 0, "UMLS": "", "start": 14}, "entity_22": {"text": "GMC", "class": "Outcome", "negation": 0, "UMLS": "", "start": 19}, "attribute_5": {"text": "highest", "class": "modifier", "negation": 0, "UMLS": "", "start": 21}, "entity_23": {"text": "PRP-T", "class": "Intervention", "negation": 0, "UMLS": "", "start": 23}, "attribute_6": {"text": "6.62 micrograms/ml ) ,", "class": "measure", "negation": 0, "UMLS": "", "start": 25}}, "relations": {}}, "sent_10": {"Section": "METHODS", "text": "by HbOC ( 1.9 micrograms/ml ) , then PRP-OMP ( 1.06 micrograms/ml ) , and lowest for the control group ( 0.11 microgram/ml ) .", "entities": {"entity_24": {"text": "HbOC", "class": "Intervention", "negation": 0, "UMLS": "", "start": 1}, "attribute_7": {"text": "1.9 micrograms/ml ) ,", "class": "measure", "negation": 0, "UMLS": "", "start": 3}, "entity_25": {"text": "1.06", "class": "Intervention", "negation": 0, "UMLS": "", "start": 10}, "attribute_8": {"text": ") , and lowest", "class": "measure", "negation": 0, "UMLS": "", "start": 12}, "attribute_9": {"text": "group", "class": "modifier", "negation": 0, "UMLS": "", "start": 19}, "entity_26": {"text": "microgram/ml", "class": "Intervention", "negation": 0, "UMLS": "", "start": 22}}, "relations": {}}, "sent_11": {"Section": "METHODS", "text": "We conclude that all three Hib conjugate vaccines ( PRP-T , HbOC , and PRP-OMP ) were immunogenic after three primary doses among Philippine infants .", "entities": {"entity_27": {"text": "Hib conjugate vaccines", "class": "Intervention", "negation": 0, "UMLS": "", "start": 5}, "entity_28": {"text": "PRP-T", "class": "Intervention", "negation": 0, "UMLS": "", "start": 9}, "entity_29": {"text": "HbOC", "class": "Intervention", "negation": 0, "UMLS": "", "start": 11}, "entity_30": {"text": "PRP-OMP", "class": "Intervention", "negation": 0, "UMLS": "", "start": 14}, "entity_31": {"text": "immunogenic", "class": "Outcome", "negation": 0, "UMLS": "", "start": 17}, "entity_32": {"text": "Philippine infants", "class": "Participant", "negation": 0, "UMLS": "", "start": 23}}, "relations": {}}}}